Week in Review: BeiGene Plans $3 Billion IPO on Shanghai STAR Market

Deals and Financings   BeiGene of Beijing has been approved to stage a $3 billion IPO on the Shanghai STAR Stock Exchange, the first biopharma to list in China , Hong Kong and the US ; Nanjing Simcere Pharma in-licensed a clinical-stage therapy for Alzheimer's disease with positive data from  Germany 's Vivoryon; HutchMed, a  Shanghai  novel drug company, completed a $537 million IPO in  Hong Kong , its third global listing; Eight Roads, Fidelity's global investment arm, launched its fifth  China  healthcare fund for  China , with $400 million to invest; Suzhou Innovent Bio will use Synaffix's antibody-drug conjugate technology to create an ADC candidate that includes an Innovent antibody; ArriVent Biopharma, a  Philadelphia  startup that will bring  China  novel drugs to global markets, raised up to $150 million in a Series A round;   Zentalis Pharma, a US-China biopharma, closed a $150 million secondary offering to advance its small molecule cancer portfolio; Sirnaomics, a Mayland-Suzhou biopharma, closed a $105 million Series E for its portfolio of RNAi therapies; Denovo Biopharma acquired global rights to an Alzheimer's disease candidate from H. Lundbeck, a  Denmark  neurological biopharma;  Trials and Approvals   Shanghai I-Mab announced that its lead bi-specific antibody assets has started a US clinical trial; Pulnovo Medical, a  Nanjing  medical device company, has completed enrollment in a  China  trial of its PADN® device, to treat pulmonary hypertension; Neurophth Biotech, a Wuhan-San Diego gene therapy company, dosed the first patient in a  China  trial of a therapy for hereditary blindness.  Stock Symbols: (NSDQ: BGNE; HK: 06160) (HK: 2096) (AM: VVY) (NASDQ/AIM: HCM; HK: 13) (NSDQ: ZNTL) (HK: 01801) (NSDQ: IMAB) Share this with colleagues: // //